US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions

Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.

Box of AstraZeneca COVID-19 vaccine
The US FDA could use data on the AstraZeneca COVID-19 vaccine to inform its review of rare blood clots seen with the Janssen vaccine. • Source: Alamy

More from Vaccines

More from Pink Sheet